Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.

Dr Liu Previews ASCO 2024 Lung Cancer Data

S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting. 


Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer. 

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Inside the Clinic: Updates in the Prevention and Treatment of Graft versus Host Disease

Videos

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, discuss recent updates in the prophylactic and treatment strategies for acute and chronic graft versus host disease (GVHD).

Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.

Indications for Allogeneic Stem Cell Transplantation in the Treatment of Hematological Malignancies

Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.

Incidence and Risk Factors of Acute and Chronic GVHD

Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.

Common Prophylaxis Regimens for GVHD

Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.

Diagnosis and Stratification of Acute and Chronic GVHD

Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.

Frontline Treatment Options for Acute GVHD

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.

Emerging Strategies for the Treatment of Acute GVHD

Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.

The Importance of Early Treatment of Chronic GVHD

Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.

Treatment Options for Steroid-Refractory Chronic GVHD

Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.

Key Investigational Approaches for Acute and Chronic GVHD

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

The Evolving Field of GVHD Treatment

Insights Video Series

Treatment Options for Steroid-Refractory Chronic GVHD

EP: 1.Indications for Allogeneic Stem Cell Transplantation in the Treatment of Hematological Malignancies

EP: 2.Incidence and Risk Factors of Acute and Chronic GVHD

EP: 3.Common Prophylaxis Regimens for GVHD

EP: 4.Diagnosis and Stratification of Acute and Chronic GVHD

EP: 5.Frontline Treatment Options for Acute GVHD

EP: 6.Emerging Strategies for the Treatment of Acute GVHD

EP: 7.The Importance of Early Treatment of Chronic GVHD

EP: 8.Treatment Options for Steroid-Refractory Chronic GVHD

EP: 9.Key Investigational Approaches for Acute and Chronic GVHD

EP: 10.The Evolving Field of GVHD Treatment

Latest Conference Coverage